In preparation for an efficacy trial of malaria vaccine SPf66 in Thailand, a series of
overlapping Phase I trials were conducted of US-manufactured SPf66. Here, two clinical lots …

The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand
that mediates erythrocyte invasion and is considered an important malaria vaccine …

Background Plasmodium falciparum (P. falciparum) malaria remains a significant cause of
mortality and morbidity throughout the world. Development of an effective vaccine would be …

Aim The review summarizes the recent empirical evidence on the efficacy, safety, and
community perception of malaria vaccines in Africa. Methods Academic Search Complete …

Summary background Malaria control programmes need to protect young children, who
bear the brunt of malaria disease and death in Africa. The development of a vaccine is a …

Background Heterologous prime boost immunization with chimpanzee adenovirus 63
(ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently …

Background Malaria infection affects the immune response to some vaccines. As Ebola virus
(EBOV) outbreaks have occurred mainly in malaria-endemic countries, we have assessed …

Background Heterologous prime-boost vaccination with chimpanzee adenovirus 63
(ChAd63) and modified vaccinia virus Ankara (MVA) encoding multiple epitope string …

The most likely mechanism to deliver a malaria vaccine in African countries is through the
Expanded Program of Immunization (EPI). So far only SPf66, a multistage synthetic peptide …

As part of the first trial of the SPf66 malaria vaccine in Africa, three randomized double-blind
placebo-controlled studies of SPf66 have been conducted in a highly endemic area of …